Australian Clinical Labs Ltd (AU:ACL)
ASX:ACL
Want to see AU:ACL full AI Analyst Report?
ACL Stock Chart & Stats
AU$2.09
AU$0.08(2.29%)
At close: 4:00 PM EST
AU$2.09
AU$0.08(2.29%)
Day’s Range― - ―
52-Week RangeAU$1.83 - AU$3.16
Previous CloseN/A
Volume421.17K
Average Volume (3M)867.30K
Market Cap
AU$344.10M
Enterprise ValueAU$792.45M
Total Cash (Recent Filing)AU$23.14M
Total Debt (Recent Filing)AU$453.61M
Price to Earnings (P/E)23.9
Beta0.95
Next Earnings
Aug 26, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend Yield4.6%
Share Statistics
EPS (TTM)0.15
Shares Outstanding187,522,400
10 Day Avg. Volume799,589
30 Day Avg. Volume867,296
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)3.09
Price to Sales (P/S)0.71
P/FCF Ratio3.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.20Price Target Upside5.26% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.16
Revenue Forecast (FY)AU$736.59M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationACL's improving free cash flow and high cash-to-income ratios indicate durable cash conversion. That sustained cash generation supports recurring dividends, funds capex or lab upgrades, and provides a buffer to deleverage or invest in efficiency over the next several quarters.
Improved Gross MarginA meaningful rise in gross margin points to better cost control or higher-value test mix. Sustained margin expansion enhances operating leverage in a low-growth environment, improving the company's ability to convert volumes into profit even if top-line growth remains modest.
Defensive, Diversified Business ModelACL operates essential diagnostic services across community, hospital and corporate channels. The diversified payer mix and contracted hospital work create recurring revenue streams driven by structural healthcare demand, providing stable baseline volumes and resilience to economic cycles.
Bears Say
High Financial LeverageA debt-to-equity ratio near 1.7 increases interest and refinancing risk, reducing strategic flexibility. High leverage can force prioritization of debt service over growth or capex, and makes the company more vulnerable to reimbursement or volume shocks over the medium term.
Low Net Profit MarginDespite better gross margins, a low net margin signals significant operating, financing or other costs that erode earnings. This limits retained earnings for reinvestment and makes dividend and deleveraging plans more sensitive to small revenue or cost swings.
Subdued Revenue And EPS TrendsVery modest top-line growth combined with declining EPS suggests pricing or volume headwinds and margin compression at the profit line. This constrains the firm's ability to improve leverage metrics or meaningfully expand margins without structural changes to pricing or service mix.
Australian Clinical Labs Ltd News
ACL FAQ
What was Australian Clinical Labs Ltd’s price range in the past 12 months?
Australian Clinical Labs Ltd lowest share price was AU$1.83 and its highest was AU$3.16 in the past 12 months.
What is Australian Clinical Labs Ltd’s market cap?
Australian Clinical Labs Ltd’s market cap is AU$344.10M.
When is Australian Clinical Labs Ltd’s upcoming earnings report date?
Australian Clinical Labs Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 98 days.
How were Australian Clinical Labs Ltd’s earnings last quarter?
Australian Clinical Labs Ltd released its earnings results on Feb 15, 2026. The company reported AU$0.067 earnings per share for the quarter, missing the consensus estimate of AU$0.073 by -AU$0.006.
Is Australian Clinical Labs Ltd overvalued?
According to Wall Street analysts Australian Clinical Labs Ltd’s price is currently Undervalued.
Does Australian Clinical Labs Ltd pay dividends?
Australian Clinical Labs Ltd pays a Semiannually dividend of AU$0.09 which represents an annual dividend yield of 4.6%. See more information on Australian Clinical Labs Ltd dividends here
What is Australian Clinical Labs Ltd’s EPS estimate?
Australian Clinical Labs Ltd’s EPS estimate is 0.1.
How many shares outstanding does Australian Clinical Labs Ltd have?
Australian Clinical Labs Ltd has 187,522,400 shares outstanding.
What happened to Australian Clinical Labs Ltd’s price movement after its last earnings report?
Australian Clinical Labs Ltd reported an EPS of AU$0.067 in its last earnings report, missing expectations of AU$0.073. Following the earnings report the stock price went up 6.768%.
Which hedge fund is a major shareholder of Australian Clinical Labs Ltd?
Currently, no hedge funds are holding shares in AU:ACL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Australian Clinical Labs Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$2.20 (5.26% Upside)
AU$2.20 (5.26% Upside)
Insider Transactions
Bought Shares
Worth AU$50.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.73%
12-Months-Change
Fundamentals
Return on Equity
16.35%
Trailing 12-Months
Asset Growth
-3.86%
Trailing 12-Months
Company Description
Australian Clinical Labs Ltd
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
ACL Stock 12 Month Forecast
Average Price Target
AU$2.20
▲(5.26% Upside)
Technical Analysis
Options Prices
Currently, No data available
---